EGFR and neoplasm: In this design, the aptamer can be replaced with specific sequences targeting other tumor biomarkers (e.g., EGFR, HER2), while the siRNA can be customized to target the key mRNAs associated with various diseases, thereby providing a foundational framework for personalized treatment.